Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression
References
- World Health Organization [Internet]. Geneva, Switzerland: World Health Organization; c2016. Cardiovascular diseases: fact sheet N°317; 2015 Jan [cited 2016 May 8]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/.
- Tellides G Pober JS. Inflammatory and immune responses in the arterial media. Circ Res. 2015 Jan 16; 116( 2): 312– 22.
- Sampson UK , Fazio S , Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012 Feb; 14( 1): 1– 10.
- Tabas I , Williams KJ , Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007 Oct 16; 116( 16): 1832– 44.
- Chinetti-Gbaguidi G , Colin S , Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol. 2015 Jan; 12( 1): 10– 7.
- Moore KJ , Sheedy FJ , Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013 Oct; 13( 10): 709– 21.
- McLaren JE , Michael DR , Ashlin TG , Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011 Oct; 50( 4): 331– 47.
- Shashkin P , Dragulev B , Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005; 11( 23): 3061– 72.
- Feng B , Yao PM , Li Y , The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol. 2003 Sep; 5( 9): 781– 92.
- Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005 Nov; 25( 11): 2255– 64.
- Lyaker MR , Tulman DB , Dimitrova GT , Pin RH , Papadimos TJ. Arterial embolism. Int J Crit Illn Inj Sci. 2013 Jan; 3( 1): 77– 87.
- Libby P. Collagenases and cracks in the plaque. J Clin Invest. 2013 Aug; 123( 8): 3201– 3.
- Robbins CS , Hilgendorf I , Weber GF , Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013 Sep; 19( 9): 1166– 72.
- Gomez D Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012 Jul 15; 95( 2): 156– 64.
- Marx SO , Totary-Jain H , Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv. 2011 Feb 1; 4( 1): 104– 11.
- Frink RJ. Inflammatory atherosclerosis: characteristics of the injurious agent. Sacramento, CA: Heart Research Foundation; 2002. Chapter 2, The smooth muscle cell. The pivot in atherosclerosis. 111 p.
- Allahverdian S , Chehroudi AC , McManus BM , Abraham T , Francis GA. Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis. Circulation. 2014 Apr 15; 129( 15): 1551– 9.
- Feil S , Fehrenbacher B , Lukowski R , Transdifferentiation of vascular smooth muscle cells to macrophage-like cells during atherogenesis. Circ Res. 2014 Sep 12; 115( 7): 662– 7.
- Shankman LS , Gomez D , Cherepanova OA , KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med. 2015 Jun; 21( 6): 628– 37.
- Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep. 2003 Jun; 5( 3): 222– 6.
- Nakano-Kurimoto R , Ikeda K , Uraoka M , Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol. 2009 Nov; 297( 5): H1673– 84.
- Kataoka Y , Puri R , Hammadah M , Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. Cardiovasc Diagn Ther. 2014 Dec; 4( 6): 460– 9.
-
Gotto
AM
Jr. The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients. Circulation. 2002 Apr 2; 105( 13): 1514– 6. - Hayek S , Canepa Escaro F , Sattar A , Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol. 2013 Feb 15; 111( 4): 532– 9.
- Ruparelia N , Digby JE , Choudhury RP. Effects of niacin on atherosclerosis and vascular function. Curr Opin Cardiol. 2011 Jan; 26( 1): 66– 70.
- Everett BM , Smith RJ , Hiatt WR. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med. 2015 Oct 22; 373( 17): 1588– 91.
- Yusuf S , Sleight P , Pogue J , Bosch J , Davies R , Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20; 342( 3): 145– 53.
- Mason RP. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Vasc Health Risk Manag. 2011; 7: 405– 16.
- Ambrose JA Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004 May 19; 43( 10): 1731– 7.
- Bäck M Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol. 2015 Apr; 12( 4): 199– 211.
- Tardif JC , L'allier P L , Ibrahim R , Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May; 3( 3): 298– 307.
- Fisk M , Gajendragadkar PR , Mäki-Petäjä KM , Wilkinson IB , Cheriyan J. Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease. Am J Cardiovasc Drugs. 2014 Jun; 14( 3): 155– 65.
- Petri MH , Tellier C , Michiels C , Ellertsen I , Dogné JM , Bäck M. Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun. 2013 Nov 15; 441( 2): 393– 8.
- Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009 May; 2( 3): 279– 85.
- Laplante M Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012 Apr 13; 149( 2): 274– 93.
- Martinet W , De Loof H , De Meyer GR. mTOR inhibition: a promising strategy for stabilization of atherosclerotic plaques. Atherosclerosis. 2014 Apr; 233( 2): 601– 7.
- Axel DI , Kunert W , Göggelmann C , Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997 Jul 15; 96( 2): 636– 45.
- Dzau VJ , Braun-Dullaeus RC , Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002 Nov; 8( 11): 1249– 56.
- Suri SS , Fenniri H , Singh B. Nanotechnology-based drug delivery systems. J Occup Med Toxicol. 2007 Dec 1; 2: 16.
- Godin B , Hu Y , La Francesca S , Ferrari M. Cardiovascular nanomedicine: challenges and opportunities. In: Homeister JW , Willis MS , editors. Molecular & translational vascular medicine. New York: Springer Science & Business Media; 2012. p. 249– 281.
- Allen TM Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004 Mar 19; 303( 5665): 1818– 22.
- Tabas I Glass CK. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 2013 Jan 11; 339( 6116): 166– 72.
- Moore KJ Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011 Apr 29; 145( 3): 341– 55.
- Sanchez-Gaytan BL , Fay F , Lobatto ME , HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages. Bioconjug Chem. 2015 Mar 18; 26( 3): 443– 51.
- Tang J , Lobatto ME , Hassing L , Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv. 2015 Apr; 1( 3): e1400223.
- Tarin C , Carril M , Martin-Ventura JL , Targeted gold-coated iron oxide nanoparticles for CD163 detection in atherosclerosis by MRI. Sci Rep. 2015 Nov 30; 5: 17135.
- Zhang J , Nie S , Martinez-Zaguilan R , Sennoune SR , Wang S. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. J Nutr Biochem. 2016 Apr; 30: 14– 23.
- Bagalkot V , Badgeley MA , Kampfrath T , Deiuliis JA , Rajagopalan S , Maiseyeu A. Hybrid nanoparticles improve targeting to inflammatory macrophages through phagocytic signals. J Control Release. 2015 Nov 10; 217: 243– 55.
- Parodi A , Quattrocchi N , van de Ven AL , Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol. 2013 Jan; 8( 1): 61– 8.
- Fang J , Nakamura H , Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011 Mar 18; 63( 3): 136– 51.
- Lobatto ME , Fayad ZA , Silvera S , Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol Pharm. 2010 Dec 6; 7( 6): 2020– 9.
- Fredman G , Kamaly N , Spolitu S , Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med. 2015 Feb 18; 7( 275): 275ra20.
- Lee GY , Kim JH , Choi KY , Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials. 2015; 53: 341– 8.
- Molinaro R , Corbo C , Martinez JO , Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater. 2016 Sep; 15( 9); 1037– 46.
DOI: https://doi.org/10.14797/mdcj-12-3-141 | Journal eISSN: 1947-6108
Language: English
Page range: 141 - 145
Published on: Jul 1, 2016
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2016 Roman A. Sukhovershin, Naama E. Toledano Furman, Ennio Tasciotti, Barry H. Trachtenberg, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.